A Multicenter, Postmarketing Observational Study to Evaluate Safety Regarding Amyloid-Related Imaging Abnormalities and Their Management in Patients With Early Alzheimer's Disease and Treated With Lecanemab
Latest Information Update: 19 Jun 2024
At a glance
- Drugs Lecanemab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Eisai Inc
Most Recent Events
- 25 Mar 2024 New trial record